Silvio Inderbitzin

Exentis 3D Screen Printing is a unique technology that allows for industrial large-scale production. Additive Screen Printing is universally applicable: For industrial parts with micro precise structures or clean room applications like tablets with active ingredients and a freely adjustable release profile. Nearly any material available in powder form can be processed to a printable paste: metals, ceramics, polymers, pharmaceutical or bio-printing products. The highly flexible additive production technology combines micro-precise part structures and rework-free part geometries with advantageous cost-benefit ratios. The cold printing process in use is sustainable and conserves materials as well as resources. Exentis is domiciled near Zurich, Switzerland, and has facilities and subsidiaries in Switzerland, Germany, and the USA. Customers, as members of the Exentis 3D community, can choose between buying their own production system or having Exentis produce millions of applications for them via contract manufacturing. At the heart of Exentis’ philosophy is the promotion of employee satisfaction, motivation, and commitment. Exentis creates attractive working conditions and supports its employees with targeted training and management programs. An open communication culture and consistently involving employees in internal decision-making processes are considered as highly relevant success factors. All employees are shareholders of Exentis and participate directly in the performance of the company.

Welcome to a new class of drug delivery systems for ODTs: Galvitas TIP-Technology! Galvita’s revolutionary, patented, and repeatedly clinically tested technology enables the production of micro capsules (Templated Inverted Particles / TIP) that can be loaded with many different active ingredients and easily compressed to tablets with excellent mechanical strength. The unique properties of TIP-based tablets offer many benefits over other oral dosage forms, such as ultra-rapid disintegration (5-10 sec), fast onset of action (reduced first-pass effect), water-free ingestion (no swallowing), smaller tablet sizes, taste masking and a neutral product composition (100% pure calcium phosphate TIP, compendial and inorganic material). Galvita offers licensing of the patented technology, value adding services in formulation development such as feasibility/early formulation, R&D and scale-up support, as well as support in setting up and conducting clinical testing and studies .

obvioTec AG is a Swiss technology company. Our unique and disruptive technology significantly improves pharma quality control, accelerates control and release processes and reduces cost. As a result, the number of recalls can be reduced and drug- and patient safety is improved. We offer managed "technology as a service”.

Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression in multiple disease areas by selective inhibition of transcription factors in the cell nucleus. The lead compound CB-103 has advanced to Phase 2 treating patients with multi-drug resistant cancers. Further, Cellestia is advancing a rich R&D pipeline of novel transcription factor inhibitors, in oncology, auto-immune and inflammatory disorders, having achieved animal in-vivo proof of concept for several new targets. Cellestia was founded in 2014 as a spin-off from EPFL, Lausanne, Switzerland and is headquartered in Basel, Switzerland.

Kinarus Therapeutics (SIX:KNRS) is a clinical-stage pharmaceutical company focused on bringing novel, patient-focused treatments for viral, respiratory, and ophthalmic diseases. Kinarus was incorporated in Basel, Switzerland in 2017. Our lead drug candidate is an oral combination of a clinical-stage P38 mitogen activated protein kinase (p38 MAPK) inhibitor, in-licensed from Roche, and a second drug, together enabling an oral, long-term effective treatment. Kinarus has launched a large Phase 2 clinical trial in hospitalized Covid-19 patients with the aim to reduce mortality and duration of hospital stay. The mechanism of action of our candidate is three-fold; reducing viral replication, inflammation, and organ damage. The trial is actively enrolling patients. Kinarus has also obtained regulatory approval for a one-year Phase 2 clinical trial in patients diagnosed with wet Age-Related Macular Degeneration. Injectable agents targeting vascular endothelial growth factor are the only approved therapies. Despite the availability of these drugs, real-world data shows significant under-treatment leading to progressive loss of vision and blindness. Kinaruss drug candidate, administered on top of anti-VEGF agents, has the potential to reduce injection frequency, providing additional therapeutic benefit and relieving the high burden to patients and their caregivers.

Aurealis Therapeutics is a Swiss-Nordic Cell and Gene Therapy Platform Company. Our multi-target cell and gene therapy platform, based on genetically modified safe lactic acid bacteria, addresses unmet medical needs: Chronic Wounds - Diabetic Foot Ulcers, Venous Ulcers, Pressure Ulcers - deadly Cancers - Ovarian Cancer, Peritoneal Carcinomatosis - Inflammation. After successfully completing our Phase 1 clinical study in Diabetic Foot Ulcer (DFU) patients with our lead clinical product AUP-16, we are initiating our Phase 2 study in Italy, Germany and Poland, first for DFU. Venous Ulcers and Pressure Ulcers will follow. In Oncology, we are building on impressive pre-clinical data with Oncolytic Bacteria lead candidate AUP-55, which shows increased survival in Ovarian Cancer and peritoneal carcinomatosis. Our pipeline also includes Inflammation, at discovery stage.

Mavena is a young Swiss company with headquarters in Walzenhausen (Appenzell) and subsidiary in Germany, which develops, manufactures and internationally markets natural-based medical products for the treatment of chronic inflammatory skin diseases. The Mavena team combines many years of experience and competence in the field of dermatology. The company builds on this base to offer innovative, effective and skin-friendly treatments to patients with skin diseases such as neurodermatitis or psoriasis. The efficacy and safety of medical devices have been proven in clinical studies and published in medical journals. The high-quality products are manufactured in one of the most modern production facility in Switzerland. With its products and expertise, Mavena is a reliable partner for patients, pharmacists and specialists. Together with them, Mavena pursues the goal of sustainably improving life with skin diseases.

NEXILIS is a Swiss MedTech company with a progressive technology that improves implant stabilization in patients with poor bone quality. This is achieved by better and more reliable anchorage of fixation screws in bone. Using the NEXILIS immediate stabilization system (ISS) results in a significantly improved interface between screws and surrounding bone. This is the base for a safe healing process and durable treatment effect.

Exentis 3D Screen Printing is a unique technology that allows for industrial large-scale production. Additive Screen Printing is universally applicable: For industrial parts with micro precise structures or clean room applications like tablets with active ingredients and a freely adjustable release profile. Nearly any material available in powder form can be processed to a printable paste: metals, ceramics, polymers, pharmaceutical or bio-printing products. The highly flexible additive production technology combines micro-precise part structures and rework-free part geometries with advantageous cost-benefit ratios. The cold printing process in use is sustainable and conserves materials as well as resources. Exentis is domiciled near Zurich, Switzerland, and has facilities and subsidiaries in Switzerland, Germany, and the USA. Customers, as members of the Exentis 3D community, can choose between buying their own production system or having Exentis produce millions of applications for them via contract manufacturing. At the heart of Exentis’ philosophy is the promotion of employee satisfaction, motivation, and commitment. Exentis creates attractive working conditions and supports its employees with targeted training and management programs. An open communication culture and consistently involving employees in internal decision-making processes are considered as highly relevant success factors. All employees are shareholders of Exentis and participate directly in the performance of the company.

Welcome to a new class of drug delivery systems for ODTs: Galvitas TIP-Technology! Galvita’s revolutionary, patented, and repeatedly clinically tested technology enables the production of micro capsules (Templated Inverted Particles / TIP) that can be loaded with many different active ingredients and easily compressed to tablets with excellent mechanical strength. The unique properties of TIP-based tablets offer many benefits over other oral dosage forms, such as ultra-rapid disintegration (5-10 sec), fast onset of action (reduced first-pass effect), water-free ingestion (no swallowing), smaller tablet sizes, taste masking and a neutral product composition (100% pure calcium phosphate TIP, compendial and inorganic material). Galvita offers licensing of the patented technology, value adding services in formulation development such as feasibility/early formulation, R&D and scale-up support, as well as support in setting up and conducting clinical testing and studies .

obvioTec AG is a Swiss technology company. Our unique and disruptive technology significantly improves pharma quality control, accelerates control and release processes and reduces cost. As a result, the number of recalls can be reduced and drug- and patient safety is improved. We offer managed "technology as a service”.

Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression in multiple disease areas by selective inhibition of transcription factors in the cell nucleus. The lead compound CB-103 has advanced to Phase 2 treating patients with multi-drug resistant cancers. Further, Cellestia is advancing a rich R&D pipeline of novel transcription factor inhibitors, in oncology, auto-immune and inflammatory disorders, having achieved animal in-vivo proof of concept for several new targets. Cellestia was founded in 2014 as a spin-off from EPFL, Lausanne, Switzerland and is headquartered in Basel, Switzerland.

Kinarus Therapeutics (SIX:KNRS) is a clinical-stage pharmaceutical company focused on bringing novel, patient-focused treatments for viral, respiratory, and ophthalmic diseases. Kinarus was incorporated in Basel, Switzerland in 2017. Our lead drug candidate is an oral combination of a clinical-stage P38 mitogen activated protein kinase (p38 MAPK) inhibitor, in-licensed from Roche, and a second drug, together enabling an oral, long-term effective treatment. Kinarus has launched a large Phase 2 clinical trial in hospitalized Covid-19 patients with the aim to reduce mortality and duration of hospital stay. The mechanism of action of our candidate is three-fold; reducing viral replication, inflammation, and organ damage. The trial is actively enrolling patients. Kinarus has also obtained regulatory approval for a one-year Phase 2 clinical trial in patients diagnosed with wet Age-Related Macular Degeneration. Injectable agents targeting vascular endothelial growth factor are the only approved therapies. Despite the availability of these drugs, real-world data shows significant under-treatment leading to progressive loss of vision and blindness. Kinaruss drug candidate, administered on top of anti-VEGF agents, has the potential to reduce injection frequency, providing additional therapeutic benefit and relieving the high burden to patients and their caregivers.